预约演示

更新于：2025-04-19

Prochlorperazine

丙氯拉嗪

更新于：2025-04-19

概要

基本信息

药物类型

小分子化药

别名

2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine、2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine、3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine

+ [11]

靶点

D2 receptor

作用方式

拮抗剂

作用机制

D2 receptor拮抗剂(多巴胺D2受体拮抗剂)

治疗领域

神经系统疾病

在研适应症-

非在研适应症

精神分裂症

原研机构

GSK Plc

在研机构-

非在研机构

GlaxoSmithKline, Inc.

最高研发阶段撤市

首次获批日期

美国 (1959-01-26),

精神分裂症

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C20H24ClN3S

InChIKeyWIKYUJGCLQQFNW-UHFFFAOYSA-N

CAS号58-38-8

关联

项与丙氯拉嗪相关的临床试验

CTRI/2024/10/075430

/ Recruiting临床4期

A Multi-Centric, Prospective, Single Arm, Open label Post Marketing Observational Study To Assess The Effectiveness And Safety Of Oral Prochlorperazine In Acute Phase In Patients Diagnosed With Benign Paroxysmal Positional Vertigo (BPPV). - NIL

开始日期2024-11-10

申办/合作机构-

CTRI/2024/08/072429

/ Not yet recruiting临床3期

An open-label phase III randomized controlled trial comparing metoclopramide, thalidomide, prochlorperazine, and lorazepam for treating breakthrough chemotherapy-induced nausea and vomiting in patients receiving olanzapine as part of antiemetic prophylaxis for highly emetogenic chemotherapy. - Nil

开始日期2024-09-01

申办/合作机构-

ACTRN12624000917538

/ Not yet recruiting临床2期IIT

Efficacy and safety of cetuximab and prochlorperazine combined for solid organ transplant patients with advanced Cutaneous Squamous Cell Carcinoma: CetPro study

开始日期2024-08-01

申办/合作机构

The University of Queensland

100 项与丙氯拉嗪相关的临床结果

登录后查看更多信息

100 项与丙氯拉嗪相关的转化医学

登录后查看更多信息

100 项与丙氯拉嗪相关的专利（医药）

登录后查看更多信息

2,177

项与丙氯拉嗪相关的文献（医药）

2025-05-01·AMERICAN JOURNAL OF EMERGENCY MEDICINE

Treatment of headache reduces blood pressure among most patients with migraine and elevated blood pressure

Article

作者: Sharpe, Shellyann ; Friedman, Benjamin W ; Kareff, Hannah ; Gupta, Chiraag

BACKGROUND:

It is unclear whether patients with elevated BP and acute headache require treatment with anti-hypertensive medication, anti-headache medication, or both. We determined the impact of migraine medication on blood pressure and pain scores among emergency department patients with moderate or severe migraine and elevated blood pressure.

METHODS:

This study uses data collected from four emergency department-based migraine clinical trials. Patients were included if they had moderate or severe migraine. Patients received one of the following medications or medication combinations: Metoclopramide + dexamethasone, metoclopramide + methylprednisolone acetate, metoclopramide + diphenhydramine, hydromorphone, or prochlorperazine+ diphenhydramine. Blood pressure and 0-10 pain scores were assessed before medication administration and 1 h later.

RESULTS:

We collected data from 729 patients. 13.3 % (97/729) had moderately elevated BP or worse. Among these patients, we identified an association between change in mean arterial pressure and change in pain (B coefficient=0.04,p=0.01) Among 53 study participants with elevated blood pressure but without a diagnosed history of hypertension, mean arterial pressure change was associated with pain score change (B. Among 44 patients with elevated blood pressure and a history of diagnosed hypertension, there was no association with mean arterial pressure (B coefficient=0.03,p=0.25). Among the 97 patients with moderately elevated blood pressure or worse, 73.2 % (95 %CI, 64.2-82.2 %) experienced an improvement in diastolic blood pressure and 78.4 % (95 %CI, 70.0-86.7) improved systolic blood pressure.

CONCLUSION:

In this analysis of data aggregated from four ED-based migraine studies, improvement in pain and blood pressure was associated among patients with acutely elevated blood pressure but without diagnosed hypertension. Most patients with elevated blood pressure who receive headache medication will experience improvement in their blood pressure over the subsequent hour.

PLAIN LANGUAGE SUMMARY:

Many patients present to emergency departments with headache and high blood pressure. A majority of these patients experienced blood pressure improvements upon treatment of their headache, and those with acutely elevated blood pressure but not diagnosed hypertension demonstrated an association between pain and blood pressure improvements. Instead of administering unnecessary anti-hypertensive medication, this research suggests that in a majority of patients, elevated blood pressure can be managed by treating the headache.

2025-03-24·ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Functionalization of Pyridines at the C4 Position via Metalation and Capture

Article

作者: Hsu, Han‐Hsiang ; Sk, Md Raja ; Thomas, Andy A. ; Chen, Cheng‐Chun ; Kang, Seokmin

Abstract:

The functionalization of pyridines at positions remote to the N‐atom remains an outstanding problem in organic synthesis. The inherent challenges associated with overriding the influence of the embedded N‐atom within pyridines was overcome using n‐butylsodium, which provided an avenue to deprotonate and functionalize the C4‐position over traditionally observed addition products that are formed with organolithium bases. In this work, we show that freshly generated 4‐sodiopyrdines could undergo transition metal free alkylation reactions directly with a variety of primary alkyl halides bearing diverse functional groups. In addition, after transmetalation to zinc chloride a simple and efficient Negishi cross‐coupling protocol was formulated for a variety of aromatic and heteroaromatic halides. The robustness of this protocol was demonstrated through the late‐stage installation of 4‐pyridyl fragments into a variety of complex active pharmaceutical ingredients including loratadine and prochlorperazine. Furthermore, through rapid injection NMR investigations, we are able to directly observe the evolution of anionic intermediates and determined that two distinct mechanistic pathways lead to the observed site selectivity: (1) the C4‐H within 2,6‐disubstituted pyridines could be removed directly and (2) the C4 selectivity of unsubstituted pyridine originates from the intermolecular exchange of metalation sites via a thermodynamic pathway.

2025-02-07·INTERNATIONAL JOURNAL OF PHARMACY PRACTICE

Nausea and vomiting in pregnancy: a cross-sectional study of community pharmacists in the UK

Article

作者: Alter, Marsha ; Lakhani, Shivali ; Williamson, Catherine ; Payne, Bradley ; Righton, Olivia ; Nana, Melanie ; Chapman, Sarah ; Flynn, Angela C ; Bell, Zoe

Abstract:

Objectives:

To assess the content and frequency of advice community pharmacists (CPs) provide to pregnant women with nausea and vomiting, their confidence in providing advice, and their knowledge of the safety of medication used to manage the condition.

Methods:

An online questionnaire of closed- and open-ended questions was distributed to CPs in the UK in May 2023. Closed-ended questions were analysed quantitatively, and conventional content analysis was utilised for open-ended responses.

Key findings:

One hundred and eighty-one respondents completed the questionnaire, 24 responses were excluded, leaving data from 157 available for analysis. The majority (90.4%) of participants reported having experience in providing advice on nausea and vomiting with varying levels of confidence. Advice provided included using over-the-counter products, lifestyle modifications, reassurance, medication advice, and referring to other healthcare professionals. Knowledge of first-line antiemetics considered safe in pregnancy varied; cyclizine was correctly identified as safe during pregnancy by 57.3%, followed by 37.6% for promethazine and 31.2% for prochlorperazine. Self-reported confidence and having experience providing advice were related to higher medication safety identification rates. Five percent of participants reported previous training on the condition, while 70% reported wanting further education, preferably delivered via an online medium.

Conclusions:

This study showed that although 90% of CPs provide advice on nausea and vomiting in pregnancy, their medication safety knowledge varied. The majority of CPs reported wanting further education that would ensure women could access reliable information and evidence-based advice to optimise management of the condition.

项与丙氯拉嗪相关的新闻（医药）

2025-02-19

·ioncology

国际视野丨Luke Peppone教授：化疗所致恶心的药物治疗进展——从丙氯拉嗪到奥氮平的临床实践变迁

编者按：在癌症治疗的征途中，化疗作为一把双刃剑，既为患者带来了生存的希望，也伴随着一系列不良反应，其中化疗所致的难治性恶心治疗起来尤为棘手。在第47届SABCS大会上，美国纽约罗切斯特大学医学癌症中心Luke Peppone教授为我们介绍了URCC 16070研究的结果（摘要号：RF2-06 ），这项全国性、双盲的III期随机对照试验，聚焦于奥氮平和丙氯拉嗪在治疗化疗所致难治性恶心中的疗效对比。肿瘤瞭望特邀Luke Peppone教授详细阐述了研究的初衷与设计，还深入分析了研究结果及其临床意义。他指出，尽管现有药物在控制呕吐方面表现优异，但恶心的控制仍需进一步优化。通过这项研究，我们有望为临床医生提供新的治疗选择，从而改善患者的生活质量。 01 《肿瘤瞭望》：您能否为我们介绍一下进行这项URCC 16070III期随机对照试验的初衷是什么？为什么选择比较奥氮平和丙氯拉嗪作为难治性化疗所致恶心的药物？ Luke Peppone教授：许多接受化疗的乳腺癌患者都有恶心和呕吐的经历。我们目前使用的药物在控制呕吐方面非常有效，能够减少90%以上的呕吐。然而，对于恶心的控制效果则相对较差，改善幅度约为50%。这是因为恶心是一个更为复杂的症状，呕吐集中在大脑的一个特定区域，而恶心则涉及多个区域。因此，尽管呕吐得到了有效控制，患者仍然会感到恶心，这种不适感显然非常困扰患者。我们有两种药物，在美国早已获批，且我们对它们的使用经验丰富。我们了解它们的安全性，药物本身也相对安全，而且对于患者群体来说，价格较为亲民，供应也很充足，市场上有大量仿制药可供选择。因此，这些药物非常容易获得，这也是我们进行这项研究的一个重要原因。 Oncology Frontier: Could you tell us about the original intention of conducting this URCC 16070 phase III randomized controlled trial? Why choose olanzapine and prochlorperazine as agents for nausea caused by refractory chemotherapy? Prof. Luke Peppone: So yeah, a lot of breast cancer patients undergoing chemotherapy will have nausea and vomiting. The drugs that we provide now are excellent at controlling vomiting with over 90% reduction. However, the control of nausea is less than that, around 50%. And that's because it's just a harder target for pharmaceuticals to hit , where vomiting is really one center in the brain, nausea is spread to a bunch. So they still have nausea despite a reduction in vomiting, which is quite unpleasant, as you can imagine. So we had two drugs, which were approved in the United States many, many years ago. And we have significant experience with these drugs. So we know their safety profile, they are definitely relatively safe, in terms of pharmaceuticals. And they are relatively cheap for our population and plentiful. They're available and generic. So it's very easy to get that. And that was sort of reason why we did this study. 02 《肿瘤瞭望》：根据研究结果，奥氮平在降低恶心程度和提高生活质量方面显著优于安慰剂，但与丙氯拉嗪相比并未显示出优越性。您如何解读这一结果？这是否意味着丙氯拉嗪更适合作为难治性化疗所致恶心的首选治疗药物？ Luke Peppone教授：这确实是个很好的问题。我们的研究结果显示，奥氮平（olanzapine）在缓解恶心方面略优于丙氯拉嗪（prochlorperazine），而且奥氮平还改善了患者的生活质量，而丙氯拉嗪则没有显现出类似的效果。这个问题并没有简单的答案，最终还需要临床医生根据患者的具体情况来做出判断。我认为，奥氮平可能是更好的选择，但丙氯拉嗪也是一个可行的替代方案。如果患者在使用奥氮平时出现过度镇静的副作用，可能需要考虑换成丙氯拉嗪，反之亦然。总的来说，这两种药物都是应对化疗引起的顽固性恶心的有效选择，奥氮平可能稍微更好，甚至可以作为首选，但最终的决定还是要根据每位患者的具体情况由临床医生来做出。 Oncology Frontier: According to the results of the study, olanzapine was significantly superior to placebo in reducing nausea and improving quality of life, but did not show superiority over prochlorperazine. How do you interpret this result? Does this mean that olanzapine is more appropriate as the first choice for the treatment of refractory chemotherapy-induced nausea? Prof. Luke Peppone: Yeah, that's a great question. Our results did show that olanzapine reduced nausea slightly more than prochlorperazine. And also, olanzapine resulted in an improvement of quality of life, where prochlorperazine did not. So it's a tough question, but it's a question that clinicians would have to answer for themselves. I would say olanzapine is probably the best choice. But I would also say that prochlorperazine is also a good choice. You might find that a patient is too sedated on olanzapine, so they might want to try prochlorperazine or vice versa. I think they're both very good options for refractory nausea and chemotherapy patients, with olanzapine potentially being a slightly better choice and perhaps the first choice, but up to each clinician. 03 《肿瘤瞭望》：在这项研究中，奥氮平和丙氯拉嗪的安全性如何？是否有患者出现严重的不良反应或需要停药的情况？您认为在选择这类药物时，需要考虑哪些患者因素以确保其安全性和耐受性？ Luke Peppone教授：在安全性方面，这两种药物的表现都非常好，研究中没有出现与奥氮平或丙氯拉嗪相关的严重不良事件。我们确实观察到了一些不良反应，但这些都是预期中的情况。奥氮平已知会引起镇静和嗜睡，这也是我们在研究中遇到的常见不良反应，丙氯拉嗪也类似，但没有出现任何意料之外的副作用。对照组和研究组的药物干预之间的不良事件发生率相似。我们还在进一步分析这些数据，但总体来说，奥氮平和丙氯拉嗪在本研究以及以往的研究中的安全性都非常好，这也是我们选择这两种药物的众多原因之一，我们也很乐意在这些患者中使用它们。 Oncology Frontier: What was the safety profile of olanzapine and prochlorperazine in this study? Did any patients have serious adverse effects or need to discontinue the drug? What patient factors do you think need to be considered to ensure safety and tolerability when selecting this class of drugs? Prof. Luke Peppone: So in terms of safety profile, both of those drugs were excellent, and we had no serious adverse events related to the study intervention drugs, either olanzapine or prochlorperazine. We had a number of adverse events that were all expected. Olanzapine is known to cause sedation and some drowsiness, and those were the typical adverse events that we dealt with, similar with prochlorperazine, but nothing unexpected. And adverse events between the placebo and the study interventions were very similar. We're still teasing apart those, but the safety profile of those two drugs in our study and in previous research are excellent, and that's one of the many reasons why they were chosen, and we like using these drugs in these patients. 04 《肿瘤瞭望》：基于这项研究结果，在临床实践中，您会如何根据患者的具体情况来制定个性化的止吐方案？这项研究结果将如何影响您的临床实践决策？ Luke Peppone教授：我本人是医学博士，并不直接进行临床治疗。不过，我有许多非常亲近的同事，他们负责患者治疗。我们所在的罗切斯特大学癌症中心在化疗引起的恶心和呕吐领域有着长期的积累，多年来我们一直使用丙氯拉嗪来控制顽固性恶心。根据这项研究的结果，越来越多的临床医生开始转向使用奥氮平，而且取得了良好的效果。患者反映恶心症状显著减轻，这表明我们的临床实践正在发生积极变化，希望这种变化能够惠及更广泛的患者群体。 Oncology Frontier: Based on the results of this study, how would you personalize your antiemetic regimen in your clinical practice? How will the results of this study affect your clinical practice decisions? Prof. Luke Peppone: Yeah, so I myself am a PhD, and I really don't treat patients. However, I have a number of very close colleagues that treat their patients. Our university at the University of Rochester Medical Center has a long history in the nausea and vomiting realm due to chemotherapy, and we have used prochlorperazine for many years to control refractory nausea, and I will say in light of this study, more of our clinicians are moving towards olanzapine, and they're having good results. Patients are saying that they are having significant reductions in nausea, so you can see that our clinical practice has slowly started changing where we are, and hopefully this trickles out to the rest of the population. Luke Peppone 纽约罗切斯特大学医学癌症中心副教授（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床结果

2025-02-19

·丁香园

患者头晕 4 年治疗无效，一张片子秒杀诊断！

5 丁香园神经科讨论群（498） @所有人看片子：52 岁女性，因自发性头晕发作就诊。自述症状已有 4 年，发作时感觉房间旋转，单次持续约 5～40 秒，每天约发生 3 次，偶尔出现恶心、呕吐。按照「梅尼埃病」给予倍他司汀、苄氟噻嗪和丙氯拉嗪治疗无效，头部 MRI 如图，考虑什么原因引起的眩晕？如何治疗？血管成袢与前庭神经接近，前庭阵发症？从影像上提示的看，考虑前庭阵发症，药物首选卡马西平，也可以选择微创手术，解除压迫。前庭神经周围有血管袢包绕，考虑前庭阵发症。尝试卡马西平。 9:30 反复短暂眩晕发作，前庭抑制剂，倍他司汀无效，左侧桥小脑三角血管袢压迫神经，考虑前庭阵发症 MRI 示左侧血管袢延伸到内耳道，有压迫左第8颅神经，考虑前庭阵发症中老年人，发作性病程，表现为发作性眩晕，无听力下降，止晕对症治疗无效，结合磁共振见血管神经压迫，考虑前庭阵发症，卡马西平有效前庭阵发症，能看到有血管和前庭神经交叉，但是大多数前庭阵发症发作时持续时间只有数秒，这个不是很典型。小脑前下动脉，小脑后下动脉，椎动脉都有可能引起，可以试用奥卡西平血管与前庭神经干扰，前庭阵发症可能，给予抗癫痫药物，去奥卡西平等，必要时减压。 @所有人公布答案：图为高分辨率 T2 加权轴位 MRI，提示左侧内听道（IAM）有一条明显的血管（箭头 A）延伸至 IAM，导致第八脑神经（箭头 B）受到压迫，诊断为：前庭阵发症（vestibular paroxysmia，VP）。本例患者服用卡马西平后症状消失。VP 是一种自发性、短暂性和反复发作的眩晕，发作通常不是由头部运动触发的，发作时长通常小于 1 分钟，发作频率高。典型 MRI 表现就是第八脑神经的神经血管压迫。 VP 的发病机制目前存在争议。「外周假说」认为，VP 的发病与神经血管交互压迫（NVCC）有关，即第八对颅神经（前庭窝神经）受邻近血管压迫和刺激，产生阵发性假性突触放电，这种病理性放电在第 Ⅷ 对颅神经轴突发生脱髓鞘损害后更易发生。相反，「中枢假说」则认为 VP 的发病机制，NVCC 只发生在神经根处，即三叉神经进入脑干处才会引起症状，在后续研究中，有学者认为这主要与颅内前庭-丘脑皮质通路激活导致中枢兴奋性增高或前庭系统受抑制有关。分享一篇VP的综述供各位参考：https://www-sciencedirect-com.libproxy1.nus.edu.sg/science/article/abs/pii/S0150986121001401

2024-11-05

·ioncology

SABCS 2024丨乳腺癌领域年终盛典将至，重磅研究汇总！

点击蓝字，关注我们编者按：第47届圣安东尼奥乳腺癌研讨会（SABCS）将于当地时间2024年12月10日至13日在美国得克萨斯州圣安东尼奥举行。日前，官网已公布摘要题目，肿瘤瞭望特将Late-Breaking Oral Presentations、General Session、Rapid Fire、Poster Spotlight Sessions等环节口头报告内容进行整理，敬请关注！ Late-Breaking Oral Presentations 时间：12月10日6:00 – 7:00 pm 地点：Stars at Night 1-2 主持人：Rita Nanda, University of Chicago Medicine, Chicago, Illinois LB1-01: Long-term effects of the omission of immediate surgery in operable breast cancer, or reduction of surgical extent: patient-level meta-analysis of the four randomised trials among 2,514 women. 可手术乳腺癌中省略即刻手术或缩小手术范围的长期影响：基于2514名女性的四项随机试验患者层面的荟萃分析讲者：Robert Hills, University of Oxford, Oxford, United Kingdom LB1-02: MARGOT/TBCRC052: A randomized phase II trial comparing neoadjuvant paclitaxel/margetuximab/pertuzumab (TMP) vs paclitaxel/trastuzumab/pertuzumab (THP) in patients (pts) with stage II-III HER2+ breast cancer. MARGOT/TBCRC052：一项随机II期临床试验，比较II-III期HER2阳性乳腺癌患者中新辅助治疗帕妥珠单抗/马吉妥昔单抗/紫杉醇（TMP）vs帕妥珠单抗/曲妥珠单抗/紫杉醇（THP）的疗效讲者：Adrienne Waks, Dana-Farber Cancer Institute, Boston, Massachusetts LB1-03: Primary results of the randomised Phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-/HR+ metastatic breast cancer and indication for chemotherapy - PADMA study. PADMA研究：比较高危HR+/HER2-转移性乳腺癌女性患者一线ET联合哌柏西利vs标准单药化疗的随机III期试验的主要结果讲者：Sibylle Loibl, German Cooperative Group, Neu-Isenburg, Germany LB1-04: Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) by pace of disease progression on prior endocrine-based therapy: additional analysis from DESTINY-Breast06. 基于既往内分泌治疗的疾病进展速度，比较德曲妥珠单抗（T-DXd） vs医生选择的化疗（TPC）的疗效与安全性：来自DESTINY-Breast06的额外分析讲者：Aditya Bardia, UCLA David Geffen School of Medicine, Los Angeles, California LB1-05: ROSC (Neo)adjuvant nab-PAC weekly vs sb-PAC q2w, followed by EC q2w, in genomically or clinically high-risk HR+/HER- early breast cancer according to ET-response: final survival results from the WSG ADAPT-HR+/HER2- chemotherapy-trial. 在遗传或临床高危HR+/HER2-早期乳腺癌中，根据ET反应（新）辅助nab-PAC周疗 vs 每2周1次sb-PAC，随后每2周1次EC：WSG ADAPT-HR+/HER2-化疗试验最终生存结果讲者：Sherko Kuemmel, German Medical Institute, Limassol, Germany LB1-06: Primary results of SOLTI VALENTINE: neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor positive (HR+)/HER2-negative (neg) early breast cancer (EBC). SOLTI VALENTINE研究的主要结果：针对高风险HR+/HER2-早期乳腺癌（EBC），比较单独使用HER3-DXd或联合使用来曲唑新辅助治疗的随机II期试验讲者：Mafalda Oliveira, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain LB1-07: Exploratory Biomarker Analysis of the Phase 3 KEYNOTE-522 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage TNBC. 3期KEYNOTE-522研究生物标志物探索性分析：对早期TNBC患者用帕博利珠单抗或安慰剂联合化疗进行新辅助治疗，随后用帕博利珠单抗或安慰剂进行辅助治疗讲者：Joyce O’Shaughnessy, Baylor-Sammons Cancer Center, Dallas, Texas General Session 1 时间：12月11日9:15 – 11:30 am 地点：Hall 1 GS1-01: Imlunestrant, an Oral Selective Estrogen Receptor Degrader (SERD), as Monotherapy and Combined with Abemaciclib, for Patients w/ ER+, HER2- Advanced Breast Cancer (ABC), Pretreated w/ Endocrine Therapy (ET): Results of the Phase 3 EMBER-3 trial. 口服选择性雌激素受体降解剂（SERD）Imlunestrant单药治疗及联合阿贝西利治疗既往接受内分泌治疗（ET）的雌激素受体阳性（ER+）、人表皮生长因子受体2阴性（HER2-）晚期乳腺癌（ABC）患者的疗效：III期EMBER-3研究结果讲者：Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, New York GS1-03: Pyrotinib or placebo in combination with trastuzumab and docetaxel for untreated HER2-positive metastatic breast cancer (mBC): prespecified final analysis of progression-free survival (PFS) of the phase 3 PHILA trial. 吡咯替尼或安慰剂联合曲妥珠单抗和多西他赛用于未接受过治疗的HER2阳性转移性乳腺癌（mBC）：III期PHILA试验预设的无进展生存期（PFS）最终分析讲者：徐兵河（中国医学科学院肿瘤医院） GS1-04: HER2-Directed Antibody-Drug Conjugate SHR-A1811 in the Neoadjuvant Treatment of HER2-positive Early Breast Cancer: a Prospective, Randomized, Open-label, Phase 2 Trial. 靶向HER2的抗体-药物偶联物SHR-A1811用于HER2阳性早期乳腺癌的新辅助治疗：一项前瞻性、随机、开放标签的2期试验讲者：李俊杰（复旦大学附属肿瘤医院） GS1-06: PRO B – a superiority randomized controlled trial evaluating the effects of symptom monitoring in metastatic breast cancer patients. PRO B ——一项评估转移性乳腺癌患者症状监测效果的优效性随机对照试验讲者：Maria Margarete Karsten, Charité-Universitätsmedizin, Berlin GS1-08: Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: results from an international cohort study. 年轻乳腺癌患者中BRCA携带者接受降低风险性手术与生存期之间的关联：一项国际队列研究结果讲者：Matteo Lambertini, University of Genova, Genova, Italy GS1-09: OlympiA- Phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/ germline BRCA1/BRCA2 pathogenic variants & high risk HER2-negative primary breast cancer; longer term follow. OlympiA长期随访——一项针对携带胚系BRCA1/BRCA2致病性变异且高危HER2阴性原发性乳腺癌患者，在（新）辅助化疗后使用辅助奥拉帕利（olaparib）的III期、多中心、随机、安慰剂对照试验讲者：Judy Garber, Dana-Farber Cancer Institute, Boston, Massachusetts Rapid Fire 1 时间：12月11日12:00 – 12:50 pm 地点：Stars at Night 1-2 主持人：Moderator: Shom Goel, University of Melbourne Peter MacCallum Cancer Centre RF1-01: Effect of a weight loss intervention (WLI) on metabolic and inflammatory biomarkers in women with obesity and breast cancer: Results from the Breast Cancer Weight Loss (BWEL) Trial (Alliance). 减重干预（WLI）对肥胖合并乳腺癌女性的代谢和炎症生物标志物的影响：乳腺癌减重（BWEL）试验（Alliance）的结果讲者：Jennifer Ligibel, Dana-Farber Cancer Institute, Boston, Massachusetts RF1-02: Palbociclib plus letrozole versus weekly paclitaxel, both in combination w/ trastuzumab plus pertuzumab, as neoadjuvant treatment for patients w/ HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17). 哌柏西利联合来曲唑对比周疗紫杉醇，两者均与曲妥珠单抗和帕妥珠单抗联用，作为HR+/HER2+早期乳腺癌患者的新辅助治疗：来自II期TOUCH随机试验（IBCSG 55-17）的主要结果讲者：Luca Malorni, USL Toscana Centro, Hospital of Prato, Prato, Italy RF1-03: Three-year event-free survival (EFS) of the multicenter phase II TRAIN-3 study evaluating image-guided optimization of neoadjuvant chemotherapy duration in stage II and III HER2-positive breast cancer (BOOG 2018-01). 多中心II期TRAIN-3研究评估了II期和III期HER2阳性乳腺癌（BOOG 2018-01）中基于影像引导的新辅助化疗持续时间优化的三年无事件生存率（EFS）讲者：Fleur Louis, Antoni van Leeuwenhoekziekenhuis, Amsterdam, Netherlands RF1-04: Long-Term Follow-up and updated analysis from S0221, Comparing Alternative Dose-Schedules of Adjuvant Anthracycline/Taxane Therapy in High-Risk Early Breast Cancer. S0221研究长期随访与更新分析：比较蒽环类/紫杉类辅助治疗高危早期乳腺癌的替代剂量方案讲者：Azka Ali, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois RF1-05: DNA methylation patterns are similar in benign tissue from ipsilateral and contralateral breast while different from matched breast cancer, and healthy controls. 同侧与对侧乳房的良性组织中的DNA甲基化模式相似，但与配对的乳腺癌组织和健康对照组存在差异讲者：Saya Dennis, Northwestern University Feinberg School of Medicine, Chicago, Illinois RF1-06: Association of polygenic-based breast cancer risk prediction with patient management. 基于多基因的乳腺癌风险预测与患者管理的相关性讲者：Katie Johansen Taber, Myriad Genetics, San Francisco, California RF1-07: Multifactor analysis for pathologic complete response (pCR) in a chemotherapy-free regimen of durvalumab, trastuzumab, and pertuzumab (DTP Trial) in HER2-enriched early breast cancer. 在HER2过表达的早期乳腺癌中，不含化疗的度伐利尤单抗、曲妥珠单抗和帕妥珠单抗方案（DTP研究）的病理完全缓解（pCR）的多因素分析讲者：Bojana Stefanovska, UT Health Science Center, San Antonio, Texas General Session 2 时间：12月12日9:00–11:45 am 地点：Hall 1 GS2-01: Exclusive endocrine therapy or radiation therapy in women aged 70+ years with luminal-like early breast cancer (EUROPA): preplanned interim analysis of a randomized phase 3 trial. 随机3期EUROPA研究预先计划的期中分析：70岁以上luminal型早期乳腺癌女性患者单纯内分泌治疗或放疗的疗效讲者：Icro Meattini, University of Florence, Florence, Italy GS2-02: Impact of Tamoxifen Only after Breast Conservation Surgery for "Good Risk" Duct Carcinoma in Situ: Results from the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trial “低风险”原位导管癌保乳术后仅采用他莫昔芬治疗的影响：NRG Oncology/RTOG 9804和ECOG-ACRIN E5194试验的结果讲者：Jean Wright, University of North Carolina School of Medicine, Chapel Hill, North Carolina GS2-03: Does postmastectomy radiotherapy in 'intermediate-risk' breast cancer impact overall survival? 10-year results of the BIG 2-04 MRC SUPREMO randomised trial: on behalf of the SUPREMO trial investigators. “中危”乳腺癌患者术后放疗是否影响总生存期？BIG 2-04 MRC SUPREMO随机试验10年结果：代表SUPREMO试验研究者讲者：Ian Kunkler, Edinburgh Cancer Centre, University of Edinburgh, Edinburgh, Scotland GS2-05: Early Oncologic Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS: the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25). 低危导管原位癌（DCIS）患者主动监测或手术（±放疗）后的早期肿瘤学结局：比较手术与监测伴或不伴内分泌治疗（COMET）研究（AFT-25）讲者：Eun-Sil Hwang, Duke University School of Medicine, Durham, North Carolina GS2-06: Patient Reported Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS in the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25). 低危导管原位癌（DCIS）患者主动监测或手术（±放疗）后的患者报告结局：比较手术与监测伴或不伴内分泌治疗（COMET）研究（AFT-25）讲者：Ann Partridge, Dana-Farber Cancer Institute, Boston, Massachusetts GS2-07: No axillary surgery versus axillary sentinel lymph node biopsy in patients with early invasive breast cancer and breast-conserving surgery: Final primary results of the Intergroup-Sentinel-Mamma (INSEMA) trial. 早期浸润性乳腺癌患者不接受腋窝手术vs接受保乳手术的腋窝前哨淋巴结活检比较：INSEMA（intergroup sentinel - mamma）试验的最终主要结果讲者：Toralf Reimer, Universitätsmedizin Rostock, Rostock, Germany GS2-09: Overweight, obesity and prognosis in 206,904 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database. 早期乳腺癌试验协作组（Early Breast Cancer trials’Collaborative Group，EBCTCG）数据库中206904名女性的超重、肥胖和预后情况讲者：Hongchao Pan, University of Oxford, Oxford, United Kingdom GS2-10: A long-term image-derived AI risk model for primary prevention of breast cancer. 用于乳腺癌一级预防的基于长期图像衍生的AI风险模型讲者：Mikael Eriksson, Karolinska Institutet, Solna, Sweden GS2-11: APOBEC3 mutagenesis induces resistance-promoting genomic alterations in breast cancer. APOBEC3突变诱导乳腺癌中促进耐药的基因组改变讲者：Avantika Gupta, Memorial Sloan Kettering Cancer Center, New York, New York Rapid Fire 2 时间：12月12日12:00 – 12:50 pm 地点：Hall 1 主持人：Carlos Arteaga, UT Southwestern, Dallas, Texas RF2-01: Factors Influencing Additional Nodal Disease and Pathologic Nodal Upstaging with Axillary Dissection in Patients with Residual Node-Positive Breast Cancer After Neoadjuvant Chemotherapy Enrolled on Alliance A011202 Clinical Trial. Alliance A011202临床试验纳入的新辅助化疗后残留淋巴结阳性乳腺癌患者中，腋窝清扫术对额外淋巴结病变和病理性淋巴结分期上调的影响因素讲者：Judy Boughey, Mayo Clinic, Rochester, Minnesota RF2-02: Axillary surgery after neoadjuvant systemic therapy (NST) for early-stage breast cancer – Treatment algorithms and prognostic impact of residual micrometastases in five neoadjuvant studies. 早期乳腺癌新辅助全身治疗（NST）后的腋窝手术——5项新辅助治疗研究中残留微转移的治疗路径和预后影响讲者：Johannes Holtschmidt, VP Medicine & Research GBG Forschungs GmbH RF2-03: Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients – results from the prospective AXSANA registry trial (NCT04373655). 初诊淋巴结阳性乳腺癌患者新辅助化疗后行腋窝超声的诊断效能——来自前瞻性AXSANA注册试验（NCT04373655）的结果讲者：Steffi Hartmann, University of Rostock, Rostock, Germany RF2-04: Ultrahypofractionated versus conventional fractionated sequential boost after whole-breast radiation therapy in breast cancer patients. One-year cosmetic outcomes of a randomized, controlled, phase 3 trial (ULTIMO). 乳腺癌患者全乳放疗后超大分割vs常规分割序贯加量疗效对比：一项随机、对照、3期试验（ULTIMO）1年美容效果讲者：Melanie Machiels, Universiteit Antwerpen, Antwerp, Belgium RF2-05: Validation of the association between TILs, ER status and benefit of radiotherapy in node positive, breast cancer patients: a DBCG study. DBCG研究：验证TILs、ER状态与淋巴结阳性乳腺癌患者放疗获益之间的关系讲者：Demet Özcan, Aarhus University Hospital, Aarhus, Denmark RF2-06: A Nationwide Double-Blind Phase III RCT Comparing Olanzapine and Prochlorperazine for Refractory Chemotherapy-Induced Nausea in NCORP Community Practices. 一项全国性、双盲、III期、随机对照试验（RCT），比较NCORP社区实践中奥氮平和丙氯拉嗪治疗化疗导致的难治性恶心讲者：Luke Peppone, University of Rochester Medical Center, Rochester, New York General Session 3 时间：12月13日9:00–11:45 am 地点：Hall 1 GS3-01: Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients w/ triple-negative breast cancer or HER2+ BRCA-mutated breast cancer with molecular residual disease after definitive therapy. ZEST是一项随机、3期、双盲研究，在尼拉帕利或安慰剂进行根治性治疗后有分子残留病变的三阴性乳腺癌或HER2+ BRCA突变乳腺癌患者中对循环肿瘤DNA进行监测。讲者：Nicholas Turner, Ralph Lauren Centre for Breast Cancer Research, London, United Kingdom GS3-03: Impact of Anthracyclines in High Genomic Risk Node-Negative HR+/HER2- Breast Cancer. 蒽环类药物对高基因组风险淋巴结阴性HR+/HER2-乳腺癌的影响讲者：Nan Chen, University of Chicago Medicine, Chicago, Illinois GS3-04: (Neo)adjuvant nab-PAC weekly vs sb-PAC q2w, followed by EC q2w, in genomically or clinically high-risk HR+/HER2- early breast cancer according to ET-response: final survival results from the WSG ADAPT-HR+/HER2- chemotherapy-trial. 在遗传或临床高危HR+/HER2-早期乳腺癌中，根据ET反应（新）辅助nab-PAC周疗 vs 每2周1次sb-PAC，随后每2周1次EC：WSG ADAPT-HR+/HER2-化疗试验最终生存结果讲者：Sherko Kuemmel, German Medical Institute, Berlin, Germany GS3-05: NSABP B-59/GBG-96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant atezolizumab or placebo in patients with Stage II and III triple-negative breast cancer. NSABP B-59/GBG-96-GeparDouze：一项针对II期和III期三阴性乳腺癌患者的随机双盲III期临床试验，比较新辅助化疗联合阿替利珠单抗或安慰剂，随后辅助使用阿替利珠单抗或安慰剂的效果讲者：Charles Geyer, University of Pittsburgh, Pittsburgh, Pennsylvania GS3-06: Neoadjuvant camrelizumab plus chemotherapy (chemo) for early or locally advanced triple-negative breast cancer (TNBC): a randomized, double-blind, phase 3 trial. 卡瑞利珠单抗联合化疗（chemo）新辅助治疗早期或局部晚期三阴性乳腺癌（TNBC）：一项随机、双盲、3期试验讲者：邵志敏（复旦大学附属肿瘤医院） GS3-08: In situ detection of individual classical MHC-I gene products in breast cancer identifies gene- and subtype-specific biased antigen presentation loss. 在乳腺癌中原位检测单个经典MHC-I基因产物，可识别出基因和亚型特异性的特异性抗原呈递缺失讲者：Paula Gonzalez-Ericsson, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee GS3-09: Multimodal integration of real world clinical and genomic data for the prediction of CDK4/6 inhibitors outcomes in patients with HR+/HER2- metastatic breast cancer. 真实世界临床和基因组数据的多模态整合用于预测CDK4/6抑制剂在HR+/HER2-转移性乳腺癌患者中的结局讲者：Enrico Moiso, Memorial Sloan Kettering Cancer Center, New York, New York GS3-10: Paired DNA and RNA analysis of CALGB 40603 (Alliance) reveals insights into the molecular and prognostic landscape of stage II-III triple-negative breast cancer. 配对的DNA和RNA分析CALGB 40603（Alliance）揭示了II-III期三阴性乳腺癌的分子和预后特征讲者：Brooke Felsheim, UNC School of Medicine, Chapel Hill, North Carolina Rapid Fire 3 时间：12月13日12:00 – 12:50 pm 地点：Hall 1 主持人：Peter Fasching, University Hospital Erlangen and Comprehensive Cancer Center Erlangen-EMN, Germany RF3-01: TBCRC 056: A phase II study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: Results from the ER+/HER2- cohort. TBCRC 056研究ER+/HER2-队列的结果：一项尼拉帕利联合dostarlimab新辅助治疗BRCA突变或PALB2突变乳腺癌患者的II期研究讲者：Erica Mayer, Dana-Farber Cancer Institute, Boston, Massachusetts RF3-02: Efficacy of adjuvant avelumab by PD-L1, tumor infiltrating lymphocytes and residual cancer burden in high-risk triple negative breast cancer: secondary and exploratory endpoints of the phase III A-BRAVE trial. 基于PD-L1、肿瘤浸润淋巴细胞和残余肿瘤负荷对高危三阴性乳腺癌进行阿维鲁单抗辅助治疗的疗效：III期A-BRAVE研究的次要和探索性终点讲者：Maria Vittoria Dieci, University of Padua, Padua, Italy RF3-03: Nivolumab + Ipilimumab (NIVO+IPI) compared to capecitabine for triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy – Final results of BreastImmune-03, a multicenter randomized open-label phase II trial. 纳武利尤单抗+伊匹木单抗（NIVO+IPI）与卡培他滨在新辅助化疗后有残留病变的三阴性乳腺癌患者中的疗效比较——多中心随机开放标签II期试验BreastImmune-03的最终结果讲者：Olivier Trédan, Centre Lèon Bèrard, Lyon, France RF3-04: NRG-BR004: A Randomized, Double-blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-line HER2-positive Metastatic Breast Cancer. NRG-BR004：紫杉烷/曲妥珠单抗/帕妥珠单抗联合阿替利珠单抗或安慰剂一线治疗HER2阳性转移性乳腺癌的随机、双盲、III期试验讲者：Vicente Valero, MD Anderson Cancer Center, Houston, Texas RF3-05: A Phase 2 Study of Neoadjuvant HER2-targeted Therapy +/- Immunotherapy with Pembrolizumab (neoHIP). 新辅助HER2靶向治疗±帕博利珠单抗免疫治疗的2期研究（neoHIP）讲者：Heather McArthur, UT Southwestern Medical Center, Dallas, Texas RF3-06: Mepitel Film for the Reduction of Radiation Dermatitis in Post-mastectomy Radiation Therapy: Results from Alliance A221803: A Multicenter Phase III Randomized Clinical Trial Mepitel贴膜在减少乳腺癌术后放疗所致放射性皮炎中的应用：Alliance A221803多中心III期随机临床试验结果讲者：Kimberly Corbin, Mayo Clinic, Rochester, Minnesota RF3-07: ROSCO:Response to Optimal Selection of neoadjuvant Chemotherapy in Operable breast cancer: A randomised phase III, stratified biomarker trial of neoadjuvant 5-Fluorouracil, Epirubicin & Cyclophosphamide vs Docetaxel & Cyclophosphamide chemotherapy. ROSCO研究：随机III期、分层生物标志物试验，比较新辅助5-氟尿嘧啶、表柔比星与环磷酰胺vs多西他赛和环磷酰胺化疗方案，评估可手术乳腺癌新辅助化疗最优选择反应。讲者：Daniel Rea, University of Birmingham, Birmingham, United Kingdom Poster Spotlight Sessions ▌Concurrent Poster Spotlight Sessions 1, 3-5, 7 Session 1: New Insights into Immune Biomarkers（免疫生物标志物的新见解）时间：12月11日7:00 – 8:30 am 地点：Room 221ABC 主持人：David Rimm, Yale University Session 3: Highlights on Novel Therapeutics（新型治疗亮点）时间：12月11日7:00 – 8:30 am 地点：Stars at Night 1-2 主持人：Sara Tolaney, Dana-Farber Cancer Institute Session 4: Prediction of Chemotherapy Response（化疗疗效预测）时间：12月11日7:00 – 8:30 am 地点：Stars at Night 3-4 主持人：Sherene Loi, Peter Macallum Cancer Centre Session 5: The Heart of the Matter - Improving Adverse Effects（核心问题-改善不良反应）时间：12月11日7:00 – 8:30 am 地点：Hemisfair Ballroom 3 主持人：Anne Blaes, Masonic Cancer Center University of Minnesota Session 7: Targeting the ER and PI3K pathway: Novel drugs and combinations（靶向ER和PI3K通路：新型药物和组合）时间：12月11日7:00 – 8:30 am 地点：Hemisfair Ballroom 1-2 主持人：Shom Goel, Peter MacCallum Cancer Centre ▌Concurrent Poster Spotlight Sessions 2, 6, 8, 9 and 15 Session 2: Personalizing CDK 4/6 inhibitor therapy for patients with Metastatic Breast Cancer: Survival, QOL and biomarkers（转移性乳腺癌患者的个体化CDK 4/6抑制剂治疗：生存期、生活质量和生物标志物）时间：12月12日7:00 – 8:30 am 地点：Hemisfair Ballroom 1-2 主持人：Lisa Carey, Lineberger Comprehensive Cancer Center University of North Carolina Session 6: Locoregional Therapy（局部区域治疗）时间：12月12日7:00 – 8:30 am 地点：Room 221ABC 主持人：Mylin Torres, Winshop Cancer Institute of Emory University Session 8: Novel HER2 Therapeutics（新型HER2治疗）时间：12月12日7:00 – 8:30 am 地点：Stars at Night 1-2 主持人：Ian Krop, Yale School of Medicine Session 9: ctDNA uses for Minimal Residual Disease testing, tumor evolution, and novel technologies（ctDNA用于微小残留病检测、肿瘤进化和新技术）时间：12月12日7:00 – 8:30 am 地点：Stars at Night 3-4 主持人：Charles Perou, Lineberger Comprehensive Cancer Center University of North Carolina Session 15: Survivorship – Biomarker predictors and other survival-associated factors（生存-生物标志物预测和其他生存相关因素）时间：12月12日7:00 – 8:30 am 地点：Room 221ABC 主持人：Lindsay Peterson, Washington University Siteman Cancer Center, St. Louis, Missouri ▌Concurrent Poster Spotlight Sessions 10-14 Session 10: Addressing Racial Disparities in Breast Cancer Outcomes（探讨乳腺癌结局的种族差异）时间：12月13日7:00 – 8:30 am 地点：Hemisfair Ballroom 3 主持人：Yara Abdou, University of North Carolina School of Medicine Session 11: Imaging to Guide Breast Cancer Treatment – Molecular Imaging and AI（影像学指导乳腺癌治疗——分子影像学和人工智能）时间：12月13日7:00 – 8:30 am 地点：Hemisfair Ballroom 1-2 主持人：David Mankoff, Perelman School of Medicine University of Pennsylvania Session 12: Immunobiology Impact on Therapeutic Efficacy（免疫生物学对治疗效果的影响）时间：12月13日7:00 – 8:30 am 地点：Room 221ABC 主持人：Lajos Pusztai, Yale School of Medicine, New Haven, Connecticut Session 13: Molecular determinants of therapeutic response and resistance - Spotight on CDK 4/6i and ADCs （治疗反应和耐药的分子决定因素——聚焦CDK4/6i和ADCs）时间：12月13日7:00 – 8:30 am 地点：Stars at Night 1-2 主持人：Aditya Bardia, UCLA David Geffen School of Medicine, Los Angeles, California Session 14: Brain Metastasis（脑转移）时间：12月13日7:00–8:30 am 地点：Stars at Night 3-4 主持人：William Gradishar, Northwestern University Feinberg School of Medicine, Chicago, Illinois （来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床结果临床2期抗体药物偶联物

100 项与丙氯拉嗪相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00493	丙氯拉嗪	N05AB04	DB00433

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
精神分裂症	美国	GlaxoSmithKline, Inc.	1959-01-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03185130 (I-FiBH, CTgov)	临床4期	头痛	58	Prochlorperazine 0.15 mg/kg up to 10 mg IV+Normal Saline 5mL+Diphenhydramine 1 mg/kg up to 50 mg IV (Standard Treatment Arm)	鹽鏇簾齋蓋鬱壓蓋遞鹹(築遞蓋蓋獵餘壓簾憲廠) = 願願齋夢選願廠簾簾積築餘積範鏇願膚糧餘壓 (積構衊鬱蓋襯鬱憲蓋願, 29.3) 更多	-	2024-06-06
				Normal Saline 20mL/kg+Prochlorperazine 0.15 mg/kg up to 10 mg IV+Diphenhydramine 1 mg/kg up to 50 mg IV (Study Arm)	鹽鏇簾齋蓋鬱壓蓋遞鹹(築遞蓋蓋獵餘壓簾憲廠) = 簾構齋餘夢膚憲簾鬱鑰築餘積範鏇願膚糧餘壓 (積構衊鬱蓋襯鬱憲蓋願, 31.0) 更多
NCT03435003 (CTgov)	临床4期	术后恶心呕吐 \| 呕吐	83	dexmedetomidine+Compazine+Total intravenous anesthesia+Fentanyl+scopolamine transdermal+sugammadex+Reglan+Propofol+Ondansetron+Aprepitant 80 mg Oral Capsule+Dexamethasone (Intervention Arm)	製膚遞鏇繭獵觸選遞願 = 獵繭廠夢夢鏇蓋憲鬱遞淵鹽餘衊積鬱餘憲構獵 (淵製範顧構淵廠廠憲選, 蓋獵襯夢蓋糧蓋艱鑰膚 ~ 糧鏇膚廠糧壓築遞醖衊) 更多	-	2024-02-14
				Compazine+sugammadex+Reglan+Sevoflurane+Desflurane+Ondansetron+Dexamethasone (Control Arm)	製膚遞鏇繭獵觸選遞願 = 製廠襯簾糧鑰遞繭鏇憲淵鹽餘衊積鬱餘憲構獵 (淵製範顧構淵廠廠憲選, 廠廠觸網憲餘製遞壓壓 ~ 簾蓋醖積築網齋鏇簾積) 更多
CNS2023	临床1/2期	偏头痛	17	Normal Saline, Prochlorperazine, Ketorolac	廠廠鬱廠壓築願淵衊鏇(膚選鬱齋夢選願壓選蓋) = 餘構壓網窪鹽顧憲蓋壓鬱製壓願繭鏇蓋廠繭淵 (積鹹蓋淵鹹範積遞繭廠 ) 更多	积极	2023-10-01
NCT01629329 (Migraine, CTgov)	临床4期	急性偏头痛	93	Aspirin, Acetaminophen, Caffeine pills (Aspirin, Acetaminophen, Caffeine Pills)	廠簾顧醖鑰蓋積積鑰餘(夢壓夢醖範夢簾製製網) = 願淵選獵構襯獵艱膚鹽獵網積憲簾餘膚糧鏇遞 (構襯醖鏇窪夢選蓋構衊, 艱襯鑰鏇餘醖廠鑰齋獵 ~ 築鹽夢鹽廠壓願鹹鹽餘) 更多	-	2020-03-18
				Prochlorperazine 10mg (Prochlorperazine 10mg)	廠簾顧醖鑰蓋積積鑰餘(夢壓夢醖範夢簾製製網) = 齋夢鬱艱襯鹽簾糧廠壓獵網積憲簾餘膚糧鏇遞 (構襯醖鏇窪夢選蓋構衊, 憲醖艱簾鑰艱積積襯膚 ~ 鹽窪顧夢窪餘艱獵糧淵) 更多
NCT02389829 (CTgov)	临床4期	急性偏头痛	127	Hydromorphone (Hydromorphone)	糧範鹽構襯淵膚願廠遞 = 鹹顧獵襯餘淵鑰簾鏇夢壓積餘構憲構製蓋製膚 (齋糧願壓壓遞範鏇齋壓, 顧窪襯鹽鏇蓋繭簾窪製 ~ 齋襯襯壓夢艱選壓構衊) 更多	-	2018-06-06
				prochlorperazine+Diphenhydramine (Prochlorperazine)	糧範鹽構襯淵膚願廠遞 = 願壓積製齋膚鏇範網淵壓積餘構憲構製蓋製膚 (齋糧願壓壓遞範鏇齋壓, 選齋構簾鬱遞膚夢夢觸 ~ 製獵糧鬱築膚鑰繭觸選) 更多
NCT00422812 (CTgov)	临床2期	先兆偏头痛	400	Inhaled Placebo (Inhaled Placebo)	艱憲壓鏇壓繭獵獵醖網 = 製襯夢壓構鹽遞製鑰範繭廠遞衊艱網襯鹹糧繭 (糧夢齋糧顧壓構襯壓餘, 選願衊鹽構獵遞遞膚製 ~ 鹹製夢鹽獵膚鹽範遞積) 更多	-	2018-01-25
				Prochlorperazine+Staccato (Inhaled PCZ 5 mg)	艱憲壓鏇壓繭獵獵醖網 = 觸顧糧襯範壓夢膚簾艱繭廠遞衊艱網襯鹹糧繭 (糧夢齋糧顧壓構襯壓餘, 醖淵網餘積顧餘築衊構 ~ 構築艱鑰鑰繭衊鹹願蓋) 更多
NCT00475085 (CTgov)	临床3期	恶心 \| 延迟性恶心和呕吐	1,021	prochlorperazine+placebo+granisetron hydrochloride+Dexamethasone (Arm II)	選鑰範蓋窪夢餘夢夢觸(繭獵鬱鏇築鬱齋襯鬱鏇) = 構艱鏇繭簾積製衊壓鏇窪簾夢齋積窪願糧積齋 (淵網顧簾蓋築憲糧顧積, 1.27) 更多	-	2013-11-03
				placebo+palonosetron hydrochloride+aprepitant+Dexamethasone (Arm III)	選鑰範蓋窪夢餘夢夢觸(繭獵鬱鏇築鬱齋襯鬱鏇) = 艱襯淵觸繭蓋構鏇選鏇窪簾夢齋積窪願糧積齋 (淵網顧簾蓋築憲糧顧積, 1.15) 更多
NCT02657031 \| NCT03185130 (Pubmed \| Ann Emerg Med)	临床4期	急性偏头痛	-	IV prochlorperazine with diphenhydramine	構築憲獵獵簾繭糧膚壓(醖窪願繭餘艱鏇廠糧構) = 餘鬱蓋簾夢築鏇獵廠鬱蓋廠膚糧窪廠鏇鑰繭願 (鏇鏇廠鬱鑰艱夢鹹鹹餘 )	积极	2010-07-01
				subcutaneous sumatriptan	構築憲獵獵簾繭糧膚壓(醖窪願繭餘艱鏇廠糧構) = 鬱網膚觸憲襯顧廠膚遞蓋廠膚糧窪廠鏇鑰繭願 (鏇鏇廠鬱鑰艱夢鹹鹹餘 )
ASCO2010	N/A	化疗引起的恶心和呕吐	96	Prochlorperazine	淵簾鹹夢鑰選夢襯廠簾(網壓願顧餘膚膚範醖簾) = 壓簾餘淵壓淵構積鹽選衊積鹹襯鹽構壓齋淵壓 (鹹選糧憲鬱遞觸淵餘鬱 )	-	2010-05-20
				5HT3 antagonists	淵簾鹹夢鑰選夢襯廠簾(網壓願顧餘膚膚範醖簾) = 衊糧醖鏇淵壓艱鹽齋鑰衊積鹹襯鹽構壓齋淵壓 (鹹選糧憲鬱遞觸淵餘鬱 )
NCT02657031 \| NCT03185130 (Pubmed \| Ann Emerg Med)	临床4期	急性偏头痛	77	Metoclopramide 20 mg	積憲醖鹽構鹹網鹹選襯(鑰築鹹繭網鹹艱壓鹽憲) = 網鹹鹹築遞積簾鹹餘壓選築築餘窪簾窪醖繭鏇 (鹽鹽範鬱蓋膚膚壓鹹範 )	-	2008-10-01